New progress of bone marrow mesenchymal stem cells in the treatment of cerebral ischemic diseases

doi:10.3877/cma.j.issn.2095-9141.2017.05.011

Abstract

Abstract:

Adult bone marrow stromal stem cells (hBMSCs) is a kind of multi potential adult stem cells derived from bone marrow. The model mechanisms of transplantation to improve cerebral ischemia model and spinal cord injury model may include replacing damaged cells, protective effect of nerve function, the induction of axon growth, and the formation of new blood vessels. Its main advantage is that it can be used in cell therapy, so there is no limit to the immune rejection, ethical problems and tumorigenicity caused by embryonic stem cell transplantation; its material is easy to be obtained, unlike neural stem cells, which are mainly located in the lower zone of the brain and hippocampus, the cell source is limited, so it is difficult to obtained. Therefore, this stem cell transplantation therapy may be of great significance in the future clinical treatment.

Key words: Bone marrow stromal stem cells, Cerebral ischemic disease, Stem cell treatment

Yongsheng Xiang, Ruxiang Xu. New progress of bone marrow mesenchymal stem cells in the treatment of cerebral ischemic diseases[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2017, 03(05): 300-304.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2017.05.011

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2017/V03/I05/300

Figures/Tables 3

References 51

[1]	Cramer SC,Finklestein SP,Schaechter JD, et al. Activation of distinct motor cortex regionsduring ipsilateral and contralateral finger movements[J]. J Neurophysiol, 1999, 81(1): 383-387.
[2]	Jiang Q,Ewing JR,Zhang ZG, et al. Magnetization transfer MRI: application totreatment of middle cerebral artery occlusion in rat[J]. J Magn Reson Imaging, 2001, 13(2): 178-184.
[3]	Chopp M,Zhang ZG,Jiang Q. Neurogenesis, angiogenesis, and MRI indices offunctional recovery from stroke[J]. Stroke, 2007, 38(2 Suppl): 827-831.
[4]	Caplan AI. Mesenchymal stem cells[J]. J Orthop Res, 1991, 9(5): 641-650.
[5]	Caplan AI,Correa D. The MSC: an injury drugstore[J]. Cell Stem Cell, 2011, 9(1): 11-15.
[6]	Caplan AI. Review: mesenchymal stem cells: cell-basedreconstructive therapy in orthopedics[J]. Tissue Eng, 2005, 11(7-8): 1198-1211.
[7]	Prockop, DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues[J]. Science, 1997, 276(5309): 71-74.
[8]	Pittenger MF,Mackay AM,Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells[J]. Science, 1997, 284(5411): 143-147.
[9]	Sanchez-Ramos J,Song S,Cardozo-Pelaez F, et al. Adult bone marrow stromal cellsdifferentiate into neural cells in vitro[J]. Exp, Neurol, 2000, 164(2): 247-256.
[10]	Kobune M,Kawano Y,Ito Y, et al. Telomerized human multipotent mesenchymalcells can differentiate into hematopoietic and cobblestone areasupportingcells[J]. Exp Hematol, 2003, 31(8): 715-722.
[11]	Azizi SA,Stokes D,Augelli BJ, et al. Engraftment and migration of human bonemarrow stromal cells implanted in the brains of albino rats –similarities to astrocyte grafts[J]. Proc Natl Acad Sci U S A, 1998, 95(7): 3908-3913.
[12]	Brazelton TR,Rossi FM,Keshet GI, et al. From marrow to brain: expression ofneuronal phenotypes in adult mice[J]. Science, 2000, 290(5497): 1775-1779.
[13]	Woodbury D,Schwarz EJ,Prockop DJ, et al. Adult rat and human bone marrow stromalcells differentiate into neurons[J]. J Neurosci Res, 2000, 61(4): 364-370.
[14]	Kim S,Honmou O,Kato K, et al. Neural differentiation potential of peripheralblood- and bone-marrow-derived precursor cells[J]. Brain Res, 2006, 1123(1): 27-33.
[15]	Massengale M,Wagers AJ,Vogel H, et al. Hematopoietic cells maintainhematopoietic fates upon entering the brain[J]. J Exp Med, 2005, 201(10): 1579-1589.
[16]	Bianco P,Robey PG,Simmons PJ, et al. Mesenchymal stem cells: revisiting history,concepts, and assays[J]. Cell Stem Cell, 2008, 2(4): 313-319.
[17]	Honma T,Honmou O,Iihoshi S, et al. Intravenous infusion of immortalized humanmesenchymal stem cells protects against injury in a cerebral ischemiamodel in adult rat[J]. Exp Neurol, 2006, 199(1): 56-66.
[18]	Chen J,Li Y,Wang L, et al. Therapeutic benefit of intravenous administrationof bone marrow stromal cells after cerebral ischemia in rats[J]. Stroke, 2001, 32(4): 1005-1011.
[19]	Li Y,Chen J,Chen XG, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery[J]. Neurology, 2002, 59(4): 514-523.
[20]	Horita Y,Honmou O,Harada K, et al. Intravenous administration of glial cell linederivedneurotrophic factor gene-modified human mesenchymal stemcells protects against injury in a cerebral ischemia model in the adultrat[J]. J Neurosci Res, 2006, 84(7): 1495-1504.
[21]	Iihoshi S,Honmou O,Houkin K, et al. A therapeutic window for intravenousadministration of autologous bone marrow after cerebral ischemia inadult rats[J]. Brain Res, 2004, 1007(1-2): 1-9.
[22]	Nomura T,Honmou O,Harada K, et al. I.V. infusion of brain-derived neurotrophicfactor gene-modified human mesenchymal stem cells protects againstinjury in a cerebral ischemia model in adult rat[J]. Neuroscience, 2005, 136(1): 161-169.
[23]	Liu H,Honmou O,Harada K, et al. Neuroprotection by PlGF gene-modified humanmesenchymal stem cells after cerebral ischaemia[J]. Brain, 2006, 129(Pt 10): 2734-2745.
[24]	Shen LH,Li Y,Chen J, et al. One-year follow-up after bone marrow stromalcell treatment in middle-aged female rats with stroke[J]. Stroke, 2007, 38(7): 2150-2156.
[25]	Chen X,Li Y,Wang L, et al. Ischemic rat brain extracts induce human marrowstromal cell growth factor production[J]. Neuropathology, 2002, 22(4): 275-279.
[26]	Chen J,Li Y,Katakowski M, et al. Intravenous bone marrow stromal cell therapyreduces apoptosis and promotes endogenous cell proliferation afterstroke in female rat[J]. J Neurosci Res, 2003, 73(6): 778-786.
[27]	Kurozumi K,Nakamura K,Tamiya T, et al. BDNF gene-modified mesenchymal stemcells promote functional recovery and reduce infarct size in the ratmiddle cerebral artery occlusion model[J]. Mol Ther, 2004, 9(6): 189-197.
[28]	Sasaki M,Radtke C,Tan AM, et al. BDNF-hypersecreting human mesenchymalstem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury[J]. J Neurosci, 2009, 29(47): 14932-14941.
[29]	Toyama K,Honmou O,Harada K, et al. Therapeutic benefits of angiogenetic genemodifiedhuman mesenchymal stem cells after cerebral ischemia[J]. Exp Neurol, 2009, 216(1): 47-55.
[30]	Onda T,Honmou O,Harada K, et al. Therapeutic benefits by human mesenchymalstem cells (hMSCs) and Ang-1 gene-modified hMSCs after cerebralischemia[J]. J Cereb Blood Flow Metab, 2008, 28(2): 329-340.
[31]	Zhang Z,Chopp M. Vascular endothelial growth factor andangiopoietins in focal cerebral ischemia[J]. Trends Cardiovasc Med, 2002, 12(2): 62-66.
[32]	Carmeliet P,Collen D. Molecular analysis of blood vesselformation and disease[J]. Am J Physiol, 1997, 273(Pt 2): H2091-H2104.
[33]	Bates DO,Hillman NJ,Williams B, et al. Regulation of microvascular permeability byvascular endothelial growth factors[J]. J Anat, 2002, 200(6): 581-597.
[34]	Sasaki M,Lankford KL,Brown RJ, et al. Focal experimental autoimmune encephalomyelitis in the Lewis rat induced by immunization withmyelin oligodendrocyte glycoprotein and intraspinal injection ofvascular endothelial growth factor[J]. Glia, 2010, 58(13): 1523-1531.
[35]	Suri C,McClain J,Thurston G, et al. Increased vascularization in miceoverexpressing angiopoietin-1[J]. Science, 1998, 282(5388): 468-471.
[36]	Yancopoulos GD,Davis S,Gale NW, et al. Vascular-specific growth factors andblood vessel formation[J]. Nature, 2000, 407(6801): 242-248.
[37]	Ward NL,Lamanna JC. The neurovascular unit and itsgrowth factors: coordinated response in the vascular and nervoussystems[J]. Neurol Res, 2004, 26(8): 870-883.
[38]	Thurston G,Suri C,Smith K, et al. Leakage-resistant bloods in micetransgenically overexpressing angiopoietin-1[J]. Science, 1999, 286(5449): 2511-2514.
[39]	Sundberg C,Kowanetz M,Brown LF, et al. Stable expression of angiopoietin-1 and othermarkers by cultured pericytes: phenotypic similarities to asubpopulation of cells in maturing vessels during later stages ofangiogenesis in vivo[J]. Lab Invest, 2002, 82(4): 387-401.
[40]	Baffert F,Le T,Thurston G, et al. Angiopoietin-1 decreases plasma leakage byreducing number and size of endothelial gaps in venules[J]. Am J Physiol Heart Circ Physiol, 2006, 290(1): H107-H118.
[41]	Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases[J]. Nat Rev Genet, 2003, 4(9): 710-720.
[42]	Dore-Duffy P,Owen C,Balabanov R, et al. Pericyte migration from the vascular wall inresponse to traumatic brain injury[J]. Microvasc Res, 2000, 60(1): 55-69.
[43]	Miki Y,Nonoguchi N,Ikeda N, et al. Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological deficits and reduced infarction volume in rat brain ischemia[J]. Neurosurgery, 2007, 61(3): 586-594.
[44]	Crisan M,Yap S,Casteilla L, et al. A perivascular origin for mesenchymal stemcells in multiple human organs[J]. Cell Stem Cell, 2008, 3(3): 301-313.
[45]	Alvarez-Buylla A,Lim DA. For the long run: maintaininggerminal niches in the adult brain[J]. Neuron, 2004, 41(5): 683-686.
[46]	Luskin MB,Zigova T,Soteres BJ, et al. Neuronal progenitor cells derived from theanterior subventricular zone of the neonatal rat forebrain continue toproliferate in vitro and express a neuronal phenotype[J]. Mol Cell Neurosci, 1997, 8(5): 351-366.
[47]	Bang OY,Lee JS,Lee PH, et al. Autologous mesenchymal stem celltransplantation in stroke patients[J]. Ann Neurol, 2005, 57(6): 874- 882.
[48]	Lee JS,Hong JM,Moon GJ, et al. A long-term follow-up study of intravenousautologous mesenchymal stem cell transplantation in patients withischemic stroke[J]. Stem Cells, 2010, 28(6): 1099-1106.
[49]	Honmou O,Houkin K,Matsunaga T, et al. Intravenous administration of auto serumexpandedautologous mesenchymal stem cells in stroke[J]. Brain, 2011, 134(Pt16): 1790-1807.
[50]	Sasaki M,Honmou O,Radtke C, et al. Development of a middle cerebral arteryocclusion model in the nonhuman primate and a safety study of I.V. infusion of human mesenchymal stem cells[J]. PLoS ONE, 2011, 6(10): e26577.
[51]	Majumdar MK,Thiede MA,Mosca JD, et al. Phenotypic and functional comparison ofcultures of marrow-derived mesenchymal stem cells(MSCs) andstromal cells[J]. J Cell Physiol, 1998, 176(1): 57-66.

Please choose a citation manager

Content to export